Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.42 |
| ▸ | SELE | P16581 | 2/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489914 | 0.91 | SLC6A4 (0.47) | AKR1C3KDM4EGLAPOLBMCL1 | |
| SCHEMBL490103 | 0.90 | MAPT (0.50) | AKR1C3AKR1C2KDM4EGLAPOLB | |
| SCHEMBL12726139 | 0.90 | SORT1 (0.46) | AKR1C3AKR1C2KDM4EGLAPOLB | |
| SCHEMBL10170971 | 0.90 | MAP3K8 (0.45) | AKR1C3AKR1C2KDM4EGLAPOLB | |
| SCHEMBL21327649 | 0.90 | KDM4E (0.54) | AKR1C3AKR1C2KDM4EPOLBMCL1 | |
| SCHEMBL19474926 | 0.88 | NCEH1 (0.46) | AKR1C3AKR1C2KDM4EGLAPOLB | |
| SCHEMBL1999191 | 0.87 | AKR1C3 (0.46) | AKR1C3AKR1C2KDM4EPOLBMCL1 | |
| Hydrochloric Acid SCHEMBL9672210 | 0.87 | TTR (0.48) | AKR1C3AKR1C2KDM4EPOLBMCL1 | |
| SCHEMBL15897450 | 0.87 | AKR1C3 (0.43) | AKR1C3AKR1C2KDM4EPOLBMCL1 | |
| SCHEMBL26936314 | 0.86 | KDM4E (0.56) | AKR1C3AKR1C2KDM4EGLAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170894-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2018-06-21 | — | — | US | disclosed |
| US-9150554-B2 | Fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150554-B2 | Fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-8999967-B2 | Tricyclic fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999967-B2 | Tricyclic fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130310427-A1 | INHIBITORS OF HCV NS5A PROTEIN | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2012050918-A2 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICAL, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2012003642-A1 | FUSED TRICYCLIC COMPOUNDS AND USE THEREOF FOR TREATING VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2010111534-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310427-A1 | INHIBITORS OF HCV NS5A PROTEIN | HAVCR2, EIF2AK2, PPP2CA | AKR1C3 3986/4885AKR1C2 3984/4885KDM4E 4223/4885 |
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | HAVCR2, HCCS, LIPC | AKR1C3 532/4885AKR1C2 1038/4885KDM4E 4230/4885 |
| US-20180170894-A1 | LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL | UBE2M, UFM1, UFL1 | AKR1C3 3993/4885AKR1C2 4235/4885KDM4E 1215/4885 |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | HAVCR2, HCCS, ZC3HAV1 | AKR1C3 968/4885AKR1C2 1452/4885KDM4E 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.